Endocrine Abstracts

Introduction: Feminizing hormone therapy (HT) for male-assigned at birth (AMAB) includes estrogens, often in combination with anti-androgens. Several studies have reported an increased incidence of cardiovascular diseases and venous thromboembolism in AMAB receiving estrogens. Indeed, procoagulant changes induced by estrogen-based HT occur in transwomen as well as in cisgender individuals. Therefore, using estrogen in gender-affirming HT is relatively contraindicated in those ...

Objective: Somatostatin analogues (SSA) are widely used for the treatment of patients with neuroendocrine tumors. These drugs are able to influence glucose metabolism by an inhibitory effect of insulin secretion, but the clinical impact of this effect is uncertain. Most of the data on this topic have been obtained from studies including patients in acromegaly, one the major indication for SSA, which are limited in terms of numerosity and study duration. Therefore, we have carr...

The Standards of Care version 8 (SOC 8) for transgender and gender diverse people suggest maintaining estradiol (E2) levels between 100-200 pg/ml in Assigned Male at Birth (AMAB) subjects who desire a complete feminization during gender affirmation hormone therapy (GAHT). However, data about estrogen dose therapy and corresponding serum concentrations are scarce, especially regarding gel formulations. Our aim was to retrospectively compare E2 serum levels in AMAB patients unde...

Adult GHD patients may have reduced BMD with high risk of vertebral and non-vertebral fractures which is thought to be reverted by long-term rhGH replacement therapy. In this study we aimed at identifying the determinant factors of vertebral fractures, as assessed by a radiological morphometric approach, in a cohort of adult patients with untreated GHD. Forty-two patients (27 males, 15 females; median age: 48 years, range: 30–67) with untreated severe (as defined by a pea...

Adult GHD patients may have reduced BMD, which is thought to be reverted by long-term rhGH replacement therapy. We have recently reported high prevalence of vertebral osteoporotic deformities in untreated adult GHD patients. Gonadal status is the main determinant of bone loss in patients with primary form of osteoporosis.In this cross-sectional study, we investigated whether the prevalence and degree of spinal deformities in adults with treated or untrea...

The effects of conventional somatostatin analog (SSA) regimens on glucose homeostasis seem to have minor clinical impact in acromegaly. Recently, we performed a trial showing that high dose octreotide LAR significantly reduces IGF1 in acromegalic patients uncontrolled with conventional SSA doses. In this post-hoc analysis, we evaluated the effects of high doses versus high frequency octreotide LAR on glucose homeostasis (HbA1c, FPG, HOMA-R) in patients with acromegaly e...

Objective: In acromegaly, 25–50% of patients remain uncontrolled with conventional somatostatin analogue (SA) therapy. Evidence suggests that response may be improved by increasing the dose or frequency of administration of SAs. This study evaluated the efficacy and safety of octreotide LAR administered at a high dose or high frequency in patients with acromegaly.Methods: This was a 24-week prospective, multicenter, randomized, open-label trial in p...